<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738357</url>
  </required_header>
  <id_info>
    <org_study_id>HSK21542-301</org_study_id>
    <nct_id>NCT04738357</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate Efficacy and Safety of HSK21542 for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, double-blind, placebo-controlled study. A total of&#xD;
      276 subjects undergoing elective laparoscopic surgery under general anesthesia are planned to&#xD;
      be enrolled and randomized into 2 groups, i.e., the HSK21542 group (138 subjects) and the&#xD;
      placebo group (138 subjects).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2021</start_date>
  <completion_date type="Anticipated">November 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Differences (SPID)</measure>
    <time_frame>Frome administration until 24 hours after administration</time_frame>
    <description>The time-weighted SPID at rest within 0-24 h after the first postoperative administration in each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences (SPID)</measure>
    <time_frame>Frome administration until 12 hours after administration</time_frame>
    <description>The time-weighted SPID at rest within 0-12 h after the first postoperative administration in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of remedial analgesics</measure>
    <time_frame>Frome administration until 24 hours after administration</time_frame>
    <description>Cumulative used amount of remedial analgesics (morphine injection, mg) within 0-12 h or 0-24 h after the first postoperative administration in each group, percentage of subjects not using remedial analgesics, and start time of remedial analgesic use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Differences（PID）</measure>
    <time_frame>Frome administration until 24 hours after administration</time_frame>
    <description>The PID at rest at each scoring time point after the first postoperative administration in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a NRS of ≤ 3</measure>
    <time_frame>Frome administration until 24 hours after administration</time_frame>
    <description>The ratio of subjects with NRS score ≤ 3 at 12 h or 24 h after the first postoperative administration in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of AEs</measure>
    <time_frame>from signing the informed consent form to the follow-up period (D8 ± 1 postoperative).</time_frame>
    <description>Adverse event/serious adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Postoperative Analgesia</condition>
  <arm_group>
    <arm_group_label>HSK21542</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>HSK21542：1 µg/kg</description>
    <arm_group_label>HSK21542</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 ≤ age ≤ 70 years old, with no gender requirement;&#xD;
&#xD;
          2. American Society of Anesthesiologists (ASA) Class I-II;&#xD;
&#xD;
          3. BMI ≥ 18 kg/m2 and ≤ 40 kg/m2;&#xD;
&#xD;
          4. Subjects undergoing elective laparoscopic surgery under general anesthesia with an&#xD;
             expected surgery duration of 1-5 h (inclusive);&#xD;
&#xD;
          5. Agree to participate in this trial and voluntarily sign the informed consent form;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With a history of allergy to opioids, such as urticaria, or allergic to intraoperative&#xD;
             anesthetics as prescribed in the protocol;&#xD;
&#xD;
          2. Patients with history or evidence of any of the following diseases prior to screening:&#xD;
&#xD;
               1. History of cardiovascular diseases: uncontrolled hypertension (systolic blood&#xD;
                  pressure [SBP] ≥ 170 mmHg and/or diastolic blood pressure [DBP] ≥ 105 mmHg&#xD;
                  without treatment, or SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg despite&#xD;
                  antihypertensive treatment), aneurysm, severe arrhythmia, heart failure,&#xD;
                  Adams-stokes syndrome, New York Heart Association (NYHA) Class ≥ III, severe&#xD;
                  superior vena cava syndrome, pericardial effusion, acute myocardial ischemia,&#xD;
                  unstable angina, myocardial infarction within 6 months before screening, history&#xD;
                  of tachycardia/bradycardia requiring medical treatment, II-III degree&#xD;
                  atrioventricular block (excluding patients with pacemakers);&#xD;
&#xD;
               2. History of respiratory system disorders: severe chronic obstructive pulmonary&#xD;
                  disease, acute exacerbation of chronic obstructive pulmonary disease, severe&#xD;
                  airway stenosis, throat mass, history of tracheoesophageal fistula or airway&#xD;
                  tear, severe respiratory infection within 2 weeks prior to screening;&#xD;
&#xD;
               3. History of neurological and psychiatric disorders: craniocerebral injury,&#xD;
                  convulsions, intracranial hypertension, cerebral aneurysms, history of&#xD;
                  cerebrovascular accidents; schizophrenia, mania, insanity, long-term use of&#xD;
                  psychotropic drugs, and history of cognitive dysfunction; history of depression,&#xD;
                  anxiety, and epilepsy, etc.;&#xD;
&#xD;
               4. Have undergone any major surgery within 3 months prior to screening, which may&#xD;
                  affect postoperative pain assessment as judged by the investigator;&#xD;
&#xD;
          3. In receipt of any one of the following medications or treatments at screening:&#xD;
&#xD;
               1. A time between the last use of opioid and non-opioid (such as paracetamol,&#xD;
                  aspirin [daily dose &gt; 100 mg], indometacin, diclofenac, parecoxib sodium, and&#xD;
                  other non-steroidal anti-inflammatory drugs) analgesics and randomization of&#xD;
                  shorter than 5 half-lives of the drug or the duration of response (whichever is&#xD;
                  longer);&#xD;
&#xD;
               2. Longer than 10 days of continuous use of opioid analgesics for any reason within&#xD;
                  3 months prior to screening;&#xD;
&#xD;
               3. Use of drugs with unknown half-life that affect the analgesic effect within 14&#xD;
                  days before randomization, or the last use of drugs that affect the analgesic&#xD;
                  effect is within 5 half-lives (as per the packaging insert of the drug) apart&#xD;
                  from randomization, such drugs include but are not limited to: sedative-hypnotics&#xD;
                  (benzodiazepines [triazolam, diazepam, midazolam, etc.], non-benzodiazepines&#xD;
                  [zolpidem, zopiclone, zaleplon, etc.]), sedative anesthetics (sevoflurane,&#xD;
                  anesthetic ether, nitrous oxide, thiopental sodium, ketamine, etomidate, etc.),&#xD;
                  glucocorticoids (dexamethasone hydrochloride, methylprednisolone, etc.),&#xD;
                  antiepileptics (carbamazepine, sodium valproate, etc.), anxiolytics&#xD;
                  (chlordiazepoxide, diazepam, etc.), antidepressants (imipramine, amitriptyline,&#xD;
                  etc.), and Chinese herbal medicines or Chinese patent medicines with analgesic&#xD;
                  and sedative effects;&#xD;
&#xD;
               4. Expected to receive any anti-tumor drug or therapy from 14 days prior to&#xD;
                  randomization to the end of the follow-up period, including but not limited to&#xD;
                  chemotherapy drugs, targeted drugs, and Chinese herbal medicines;&#xD;
&#xD;
               5. A time between randomization and the last use of diuretics and compound drugs&#xD;
                  containing diuretics of shorter than 5 half-lives of the drug or the duration of&#xD;
                  response (whichever is longer);&#xD;
&#xD;
          4. The laboratory parameters measured at screening period reach one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. WBC &lt; 3.0 × 109/L;&#xD;
&#xD;
               2. Platelet count &lt; 80 × 109/L;&#xD;
&#xD;
               3. Hemoglobin &lt; 70 g/L;&#xD;
&#xD;
               4. Prothrombin time &gt; 1.5 × ULN;&#xD;
&#xD;
               5. Activated partial thromboplastin time &gt; 1.5 × ULN;&#xD;
&#xD;
               6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt; 2 × ULN;&#xD;
&#xD;
               7. Total bilirubin &gt; 1.5 × ULN;&#xD;
&#xD;
               8. Blood creatinine &gt; 1.5 × ULN;&#xD;
&#xD;
               9. Fasting blood glucose ≥ 11.1 mmol/L;&#xD;
&#xD;
          5. Positive for hepatitis C antibody (HCVAb), syphilis antibody, or human&#xD;
             immunodeficiency virus (HIV) antibody at screening;&#xD;
&#xD;
          6. History of medication or drug abuse and/or alcohol abuse within 3 months prior to&#xD;
             screening (alcohol abuse is defined as an average of &gt; 2 units of alcohol consumed per&#xD;
             day [1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol, or 150&#xD;
             mL of wine]);&#xD;
&#xD;
          7. History of blood donation or blood loss of ≥ 400 mL within 3 months prior to&#xD;
             screening;&#xD;
&#xD;
          8. Have participated in other clinical trials within 3 months prior to screening (defined&#xD;
             as having received investigational product or placebo);&#xD;
&#xD;
          9. Pregnant or breastfeeding females; women of child-bearing potential or men who are&#xD;
             unwilling to use contraception during the trial; or subjects who are planning&#xD;
             pregnancy within 3 months after the completion of the trial (including male subjects);&#xD;
&#xD;
         10. Subject judged by the investigator to have any other factors unsuitable for&#xD;
             involvement in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

